Elevar Therapeutics Debuts New Corporate Headquarters in Fort Lee, New Jersey
07 mars 2023 09h00 HE
|
Elevar Therapeutics
FORT LEE, N.J., March 07, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
Elevar Therapeutics Announces Positive Pre-NDA Meeting for Rivoceranib Combination With Camrelizumab as Hepatocellular Carcinoma Treatment Option
11 oct. 2022 16h00 HE
|
Elevar Therapeutics
SALT LAKE CITY, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui Pharma
10 sept. 2022 04h00 HE
|
Elevar Therapeutics
Top-line findings were presented today at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive pivotal trial to show survival benefits with a PD-1 inhibitor...
Elevar Therapeutics Announces Camrelizumab Plus Rivoceranib Significantly Prolonged Overall Survival and Progression-Free Survival Versus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma During Phase 3 Trial, a Joint Program With Hengrui Pharma
07 sept. 2022 18h05 HE
|
Elevar Therapeutics
Top-line findings will be presented Sept. 10 at the annual European Society for Medical Oncology (ESMO) Congress This is the first positive pivotal trial to show survival benefits with a PD-1...
Elevar Therapeutics Announces Data From Phase 3 Study of Rivoceranib in Combination With Camrelizumab Is Accepted for Late-Breaking Proffered Paper Presentation at ESMO Congress 2022
25 août 2022 07h00 HE
|
Elevar Therapeutics
SALT LAKE CITY, Aug. 25, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
Elevar Therapeutics Names Wade Smith Chief Financial Officer
22 août 2022 09h01 HE
|
Elevar Therapeutics
SALT LAKE CITY, Aug. 22, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
Elevar Therapeutics Names Dr. Jan M. Van Tornout Chief Medical Officer, Dr. Gordon Schooley Chief Regulatory Officer
28 juin 2022 14h35 HE
|
Elevar Therapeutics
SALT LAKE CITY, June 28, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...
Elevar Therapeutics Shares Results of Phase 2 Rivoceranib Trial in Patients with Progressive Recurrent or Metastatic Adenoid Cystic Carcinoma
06 juin 2022 17h30 HE
|
Elevar Therapeutics
CHICAGO, June 06, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who have...
Elevar Therapeutics Adds Drs. Honghui Zhou and David Lilienfeld as Vice Presidents
02 juin 2022 14h26 HE
|
Elevar Therapeutics
Biopharmaceutical company promotes Jennifer Lee to senior vice president of clinical operations, data management and biostatistics SALT LAKE CITY, June 02, 2022 (GLOBE NEWSWIRE) -- Elevar...
Elevar Therapeutics Announces Rivoceranib Demonstrated Clinical Effectiveness in Patients with Progressive Recurrent or Metastatic Adenoid Cystic Carcinoma in a Phase 2 Trial
26 mai 2022 17h00 HE
|
Elevar Therapeutics
Results of open-label, multicenter study will be presented during a poster session at ASCO on June 6 Rivoceranib represents a potential new treatment option for patients with R/M ACC who have...